Head to head
Alamar Biosciences vs Abbott Laboratories
Side-by-side on the measures that matter, with a plain-English read. Full detail: ALMR · ABT
ALMR
Alamar Biosciences
26.48-7.67%
1-year price shape — not enough history yet
Quant Rating C · 0/100
vs
ABT
Abbott Laboratories
103.00-0.84%
1-year price shape — -15% over the period
Quant Rating D · 22/100
1-year performance, rebased to 100
Abbott Laboratories edges it on the scoreable measures. Abbott Laboratories has the highest Quant Rating (22); Abbott Laboratories pays the highest dividend yield; Abbott Laboratories earns the most per share.
| ALMR | ABT | |
|---|---|---|
| Snapshot | ||
| Sector | Medical Devices | Medical Devices |
| Last price | 26.48 | 103.00 |
| Change today | -7.67% | -0.84% |
| 1-year return | -- | -15.4% |
| Market cap | $1.84B | $178.39B |
| 52-week range | 18.85 – 39.61 | 80.89 – 126.70 |
| Valuation | ||
| P/E (TTM) | -23.01 | 38.29 |
| P/E percentile, own 5-yr range | 97th | 99th |
| P/B | 6.06 | 3.50 |
| Dividend yield | 0.00% | 2.41% |
| Profitability & growth | ||
| EPS (TTM) | -0.54 | 3.72 |
| Net profit (TTM) | $-37.52M | $6.44B |
| Revenue (TTM) | $114.05M | $48.23B |
| Provider revenue period date | 2026-09-29 | 2026-09-29 |
| Revenue growth (YoY) | +68.5% | +14.5% |
| Gross margin | 59.3% | 56.9% |
| Operating margin | -42.1% | 13.8% |
| Net margin | -48.2% | 9.7% |
| Free cash flow (TTM) | $-69.05M | $6.76B |
| Provider cash-flow period date | 2026-09-29 | 2026-09-29 |
| Ownership & sentiment | ||
| Institutional ownership | 65.1% | 81.2% |
| Insider activity (12mo) | 23 buy / 24 sell | 36 buy / 12 sell |
| Short interest (% of float) | 3.2% | 1.1% |
| Analyst consensus | 50% buy / 50% hold (2) | 93% buy / 7% hold (15) |
| Analyst price target | $36 (+36%) | $122 (+18%) |
| StockVane view | ||
| StockVane Quant Rating | C (0) | D (22) |
| Company | ||
| Employees | 222 | 115,000 |
| Founded | 2018 | 1900 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.